Clinical analysis and prognostic factors including Neutrophil-to-lymphocyte ratio (NLR) provide prognostic value for efficacy of bevacizumab in HER2 negative metastatic breast cancer

First Author / 第一作者

Wen chi Wu

Institution / 單位

Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan

Audio / 音訊檔

Author Group / 作者群

Wenchi Wu, M.D. 1 Chi-Cheng Huang, MD. PhD2,3 . Yi-Fang Tsai, MD. PhD2,3. Ta-Chung Chao, MD. PhD1,2. Chun-Yu Liu, MD. PhD1,2. Ling-Ming Tseng, MD. PhD2,3. Jiun-I Lai, MD. PhD1,2.

Author Group Institution/ 作者群單位

1. Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan. 2. Comprehensive Breast Center, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan. 3. Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan 4. National Yang-Ming Chiao Tung University, Taipei, Taiwan, Taipei Veterans General Hospital, Taipei, Taiwan

Category / 主題分類

Clinical Research

Keyword / 關鍵字

bevacizumab, breast cancer, metastatic

Back to list